十一批药品集采启动报量，官方加强监管强调要“真实报量”

Core Points - The eleventh batch of drug centralized procurement has been initiated, with new flexible reporting rules allowing medical institutions to report drug usage based on brand names [1][2] - The National Medical Insurance Administration emphasizes the importance of "real reporting" and will scrutinize institutions that report below 80% of the average procurement volume [1][3] - Medical institutions are encouraged to participate in the procurement process, including public grassroots medical institutions and private medical institutions [1][2] Group 1 - The new rule allows medical institutions to report drug quantities either by type or by brand, with no limit on the number of brands reported [2] - If a reported brand is selected, it becomes the supplier for the medical institution, while unselected brands will be supplied by the main supplier in the province [2][3] - The National Medical Insurance Administration will strengthen supervision of the reporting process, requiring total reported quantities to be at least 80% of the average procurement volume for 2023 and 2024 [2][3] Group 2 - The timeline for the reporting process includes account setup by August 5, official reporting starting on August 6, and submission of data by August 25 [4] - By August 27, provinces must complete the review of reported procurement needs and submit the summarized data to the centralized procurement office [4]